نتایج جستجو برای: interferon gamma 1b

تعداد نتایج: 185145  

2016
Ludwig Kappos Gilles Edan Mark S. Freedman Xavier Montalbán Hans-Peter Hartung Bernhard Hemmer Edward J. Fox Frederik Barkhof Sven Schippling Andrea Schulze Dirk Pleimes Christoph Pohl Rupert Sandbrink Gustavo Suarez Eva-Maria Wicklein S Strasser-Fuchs T Berger K Vass C Sindic B Dubois D Dive V Delvaux J Debruyne L Metz G Rice M Kremenchutzky P Duquette Y Lapierre M Freedman A Traboulsee P O'Connor P Stourac R Talab M Valis O Zapletalova I Kovarova E Medova J Fiedler J Frederiksen B Brochet T Moreau P Vermersch J Pelletier G Edan M Clanet B David P Clavelou C Lebrun-Frenay O Gout M Kallela T Pirttila J Ruutiainen JP Erälinna K Koivisto M Reunanen I Keskinarkus I Elovaara A Villringer H Altenkirch L Bauer M Ghazi C Pohl K Wessel H-P Hartung W Steinke B Kieseier H Kolmel P Oschmann M Berghoff R Diem B Kitze A Dressel F Hoffmann K Baum S Jung H Felicitas Petereit D Reske M Sailer J Kohler B Tackenberg L Klotz R Hohlfeld T Kuempfel K-H Henn A Steinbrecher K Angstwurm H Tumani R Gold P Rieckmann C Kleinschnitz R Komoly G Gacs G Jakab G Panczel T Csepany L Csiba L Vecsei A Miller D Karussis J Chapman A Ghezzi G Comi V Martinelli P Gallo V Cosi R Bergamaschi L Durelli P Cavalla CH Polman F Barkhof B Uitdehaag B Anten R Hupperts L Visser K-M Myhr A Szczudlik K Selmaj Z Stelmasiak H Barosik-Psujek R Podemski Z Maciejek S Wawrzyniak L Cunha S Sega-Jazbec X Montalbán T Arbizu A Saiz Hinarejos J Barcena S Martínez Yélamos R Arroyo O Fernandez G Izquierdo Ayuso B Casanova i Estruch J Lycke L Kappos A de Vera S Wu E-W Radue J Kuhle H Mattle K Beer R Coleman DH Miller J Chataway J O'Riordan S Howell HF McFarland J Kesselring AJ Petkau KV Toyka

OBJECTIVE To assess outcomes for patients treated with interferon beta-1b immediately after clinically isolated syndrome (CIS) or after a short delay. METHODS Participants in BENEFIT (Betaferon/Betaseron in Newly Emerging MS for Initial Treatment) were randomly assigned to receive interferon beta-1b (early treatment) or placebo (delayed treatment). After conversion to clinically definite mult...

2015
Georgios Hadjigeorgiou Efthimios Dardiotis Georgios Tsivgoulis Triantafyllos Doskas Damianos Petrou Nikolaos Makris Nikolaos Vlaikidis Thomas Thomaidis Athanasios Kyritsis Nikolaos Fakas Xoulietta Treska Clementine Karageorgiou Stefania Sotirli Christos Giannoulis Dimitra Papadimitriou Ioannis Mylonas Evaggelos Kouremenos George S. Vlachos Dimitrios Georgiopoulos Despoina Mademtzoglou Michalis Vikelis Elias Zintzaras

Georgios Hadjigeorgiou, Efthimios Dardiotis, Georgios Tsivgoulis, Triantafyllos Doskas, Damianos Petrou, Nikolaos Makris, Nikolaos Vlaikidis, Thomas Thomaidis, Athanasios Kyritsis, Nikolaos Fakas, Xoulietta Treska, Clementine Karageorgiou, Stefania Sotirli, Christos Giannoulis, Dimitra Papadimitriou, Ioannis Mylonas, Evaggelos Kouremenos, George S. Vlachos, Dimitrios Georgiopoulos, Despoina Mad...

Journal: :Journal of neurology, neurosurgery, and psychiatry 2003
C Milanese L La Mantia R Palumbo V Martinelli A Murialdo M Zaffaroni D Caputo R Capra R Bergamaschi

BACKGROUND Interferon beta 1b (Betaferon) and 1a (Avonex) were licensed in Italy for treating relapsing-remitting multiple sclerosis in February 1996 and August 1997, respectively. OBJECTIVES To evaluate the effectiveness of these agents on the basis of clinical experience in northern Italian multiple sclerosis centres. DESIGN Clinical data on patients with relapsing-remitting multiple scle...

Journal: :Danish medical bulletin 2008
L Bender J Thaarup K Varming H Krarup S Ellermann-Eriksen F Ebbesen

INTRODUCTION In this study we tested how a combination of early and late paraclinic markers could predict early onset neonatal sepsis (EONS). METHODOLOGY The first 24 hours after the suspicion of EONS, we measured interleukine (IL)-6, IL-8, IL-10, IL-18, tumor necrosis factor-alpha (TNF-alpha), interferon gamma (INF-gamma), procalcitonin (PCT) and C-reactive protein (CRP) at 8-hour intervals ...

Journal: :Journal of virology 2004
C Rollier E Depla J A R Drexhage E J Verschoor B E Verstrepen A Fatmi C Brinster A Fournillier J A Whelan M Whelan D Jacobs G Maertens G Inchauspé J L Heeney

Prophylactic hepatitis C virus (HCV) vaccine trials with human volunteers are pending. There is an important need for immunological end points which correlate with vaccine efficacy and which do not involve invasive procedures, such as liver biopsies. By using a multicomponent DNA priming-protein boosting vaccine strategy, naïve chimpanzees were immunized against HCV structural proteins (core, E...

2014
Mohammad Hossein Boskabady Ali Neamati Saleh Mohaghegh Hazrati Mohammad Reza Khakzad Shakeeb Hassan Moosavi Zahra Gholamnezhad

OBJECTIVE The effects of natural adjuvants on lung inflammation and tracheal responsiveness were examined in sensitized guinea pigs. METHODS The responses of guinea pig tracheal chains and the serum levels of interleukin-4 and interferon-gamma were examined in control pigs and three other groups of guinea pigs: the sensitized group and two other sensitized groups treated with either adjuvant ...

Journal: :Chemical biology & drug design 2008
Marcio L De Paula Fernanda G Braga Elaine S Coimbra Arturene M L Carmo Henrique C Teixeira Adilson D Da Silva Maria A Souza Ana Paula Ferreira

The immunological activity of macrophages against pathogens in hosts includes the phagocytosis and the production of nitric oxide. We report herein the investigation of the effect of 6-carboxymethylthiopurine on nitric oxide production by murine macrophages as well as its effect on the cell viability and proliferation after stimulus with Mycobacterium bovis bacille Calmette-Guérin, interferon-g...

2012
Chiara Zecca Nikhil Yawalkar Claudio Gobbi

BACKGROUND The spectrum of side effects related to interferon beta-1b (INF-1b) treatment may compromise long-term adherence. METHODS Five INF-1b-treated multiple sclerosis patients with poor skin tolerability and clinical stability were instructed to dissolve the established (250 μg) INF-1b dose in half (0.5 mL) the standard diluent (1.0 mL, 0.54% sodium chloride solution), and were followed ...

2009
Damiano Paolicelli Vita Direnzo Maria Trojano

Multiple sclerosis (MS) is the most common autoimmune illness of the central nervous system. For many years the inflammatory manifestations of MS were treated using only corticosteroids. Since the 1990s the results of several clinical trials with immunomodulatory agents have changed the therapeutic approach to this disease. Interferon beta (IFNbeta)-1b represents the pioneer of those therapies....

Journal: :Acta clinica Croatica 2009
Aleksandar Jesić Dragana Stefanović Nenad Delibasić Marija Semnic Lorand Sakallasz Dragica Dobrenov Zeljko Zivanović Tamara Rabi-Zikić Milorad Zikić

The aim of this prospective study was to evaluate therapeutic effects in a cohort of 32 patients with relapsing-remitting multiple sclerosis (RRMS) that were continuously treated with interferon beta-1b during a three-year period and to compare the results obtained with literature data available. Additionally, dropouts and side effects were assessed. The annual relapse rate at three years of tr...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید